Design Therapeutics Competitors

Design Therapeutics (NASDAQ:DSGN) and VIZIO (NYSE:VZIO) are both -- companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and target prices for Design Therapeutics and VIZIO, as reported by MarketBeat.com.

Design Therapeutics currently has a consensus target price of $35.3333, suggesting a potential upside of 33.94%. VIZIO has a consensus target price of $30.00, suggesting a potential upside of 9.45%. Given Design Therapeutics' higher probable upside, analysts clearly believe Design Therapeutics is more favorable than VIZIO.

Earnings & Valuation

This table compares Design Therapeutics and VIZIO's top-line revenue, earnings per share and valuation.

Profitability

This table compares Design Therapeutics and VIZIO's net margins, return on equity and return on assets.

Summary

VIZIO beats Design Therapeutics on 2 of the 3 factors compared between the two stocks.

Design Therapeutics (NASDAQ:DSGN) and DigitalOcean (NASDAQ:DOCN) are both -- companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Earnings and Valuation

This table compares Design Therapeutics and DigitalOcean's top-line revenue, earnings per share and valuation.

Profitability

This table compares Design Therapeutics and DigitalOcean's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Design Therapeutics and DigitalOcean, as provided by MarketBeat.

Design Therapeutics currently has a consensus target price of $35.3333, indicating a potential upside of 33.94%. DigitalOcean has a consensus target price of $58.30, indicating a potential upside of 52.14%. Given DigitalOcean's stronger consensus rating and higher probable upside, analysts plainly believe DigitalOcean is more favorable than Design Therapeutics.

Summary

DigitalOcean beats Design Therapeutics on 3 of the 3 factors compared between the two stocks.

SEMrush (NASDAQ:SEMR) and Design Therapeutics (NASDAQ:DSGN) are both -- companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares SEMrush and Design Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for SEMrush and Design Therapeutics, as reported by MarketBeat.

SEMrush currently has a consensus price target of $19.75, indicating a potential upside of 11.27%. Design Therapeutics has a consensus price target of $35.3333, indicating a potential upside of 33.94%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Design Therapeutics is more favorable than SEMrush.

Profitability

This table compares SEMrush and Design Therapeutics' net margins, return on equity and return on assets.

Summary

Design Therapeutics beats SEMrush on 2 of the 3 factors compared between the two stocks.

The Duckhorn Portfolio (NYSE:NAPA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap -- companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares The Duckhorn Portfolio and Design Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares The Duckhorn Portfolio and Design Therapeutics' revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for The Duckhorn Portfolio and Design Therapeutics, as provided by MarketBeat.com.

The Duckhorn Portfolio currently has a consensus price target of $20.7778, suggesting a potential upside of 22.29%. Design Therapeutics has a consensus price target of $35.3333, suggesting a potential upside of 33.94%. Given Design Therapeutics' higher probable upside, analysts clearly believe Design Therapeutics is more favorable than The Duckhorn Portfolio.

Summary

The Duckhorn Portfolio beats Design Therapeutics on 2 of the 3 factors compared between the two stocks.

Design Therapeutics (NASDAQ:DSGN) and ThredUp (NASDAQ:TDUP) are both small-cap -- companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares Design Therapeutics and ThredUp's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Design Therapeutics and ThredUp, as provided by MarketBeat.

Design Therapeutics presently has a consensus price target of $35.3333, suggesting a potential upside of 33.94%. ThredUp has a consensus price target of $19.8571, suggesting a potential upside of 2.83%. Given Design Therapeutics' higher probable upside, analysts plainly believe Design Therapeutics is more favorable than ThredUp.

Profitability

This table compares Design Therapeutics and ThredUp's net margins, return on equity and return on assets.

Summary

ThredUp beats Design Therapeutics on 2 of the 3 factors compared between the two stocks.

PLBY Group (NASDAQ:PLBY) and Design Therapeutics (NASDAQ:DSGN) are both small-cap -- companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares PLBY Group and Design Therapeutics' revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations for PLBY Group and Design Therapeutics, as provided by MarketBeat.

PLBY Group currently has a consensus target price of $32.6667, suggesting a potential downside of 29.34%. Design Therapeutics has a consensus target price of $35.3333, suggesting a potential upside of 33.94%. Given Design Therapeutics' higher possible upside, analysts clearly believe Design Therapeutics is more favorable than PLBY Group.

Profitability

This table compares PLBY Group and Design Therapeutics' net margins, return on equity and return on assets.

Summary

PLBY Group beats Design Therapeutics on 2 of the 3 factors compared between the two stocks.